Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
15 hedge funds and large institutions have $2.65M invested in Titan Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 10 closing their positions.
2,186% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $59K
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
38% less funds holding
Funds holding: 24 → 15 (-9)
67% less capital invested
Capital invested by funds: $8.07M → $2.65M (-$5.42M)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$147K |
| 3 |
SIM
Spark Investment Management
New York
|
+$66.7K |
| 4 |
Bank of New York Mellon
New York
|
+$53.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.38M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.94M |
| 3 |
Millennium Management
New York
|
-$277K |
| 4 |
Renaissance Technologies
New York
|
-$275K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$225K |
TTNP Hedge Fund Activity: Q1 2016 in Review
15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2016, worth a combined $2.65M — down 67% from $8.07M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TTNP and 1 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $1M. The largest seller was Broadfin Capital, exiting entirely with an estimated $3.38M sold.
- 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2016, down from 24 in Q4 2015.
- Funds reported $2.65M of Titan Pharmaceuticals stock for Q1 2016, down 67% quarter-over-quarter.
- 1 fund opened new Titan Pharmaceuticals positions in Q1 2016 and 10 closed out, a net change of -9 holders.
- The largest Titan Pharmaceuticals buyer in Q1 2016 was Vanguard Group, an estimated $1M added.
- The largest Titan Pharmaceuticals seller in Q1 2016 was Broadfin Capital, an estimated $3.38M sold.
Based on aggregated 13F filings for Q1 2016.